New Guidelines: Statins May Be Needed Earlier to Prevent Heart Disease

Major changes in cardiovascular disease prevention recommendations released Friday suggest that individuals as young as 30 – a reduction from the previous age of 40 – should consider statins or other cholesterol management strategies. The updated guidelines represent a more comprehensive approach to preventing and treating heart disease, moving beyond a sole focus on LDL (“subpar”) cholesterol and statin medications.

The modern recommendations encourage behavioral changes or medication when LDL cholesterol reaches 160 mg/dL or higher in individuals without existing heart disease, beginning in young adulthood. This approach considers factors like family history of early heart disease and a risk assessment indicating a higher 30-year likelihood of developing cardiovascular disease. For those whose cholesterol levels don’t respond sufficiently to diet and exercise, imaging to assess calcium buildup in coronary arteries can help determine the need for medication before a decision is made.

“These guidelines represent an key shift toward identifying higher-risk individuals earlier and treating them more effectively,” said Gregg Fonarow, a cardiologist and professor at UCLA, in an email. STAT News reported on his comments. “This proves deeply concerning that so many cardiovascular events occur each year that could have been prevented with earlier identification and treatment of risk. These new guidelines provide a clearer, more contemporary roadmap that can help reduce this burden.”

The guidelines, developed by the American College of Cardiology, the American Heart Association, and nine other medical organizations, are based on a new risk calculator released in November 2024. This calculator is considered more reliable than previous equations due to its use of more comprehensive data.

Earlier Recognition of Risk

Earlier intervention hinges on evaluating both 10-year and 30-year risk estimates. The new PREVENT equations categorize 10-year cardiovascular disease risk as low (under 3%), borderline (3% to 5%), intermediate (5% to 10%), and high (10% or higher). These categories guide treatment decisions, ranging from initiating statin therapy to determining the intensity of lipid-lowering measures. Factors such as family history, inflammatory diseases, diabetes, kidney disease, cancer, HIV, and certain reproductive conditions all influence risk calculation.

Treatment recommendations now target lower LDL levels based on an individual’s health status. For primary prevention of a first heart attack or stroke, LDL should be under 100 mg/dL for those at borderline or intermediate risk and under 70 mg/dL for those at high risk. However, individuals with existing fatty buildup in their arteries, considered very high risk, should aim for LDL levels below 55 mg/dL.

Roger Blumenthal, chair of the guideline writing committee and director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, likened lipid-lowering drugs to blood pressure medications. He emphasized that the longer both are controlled, the greater the protection against future heart attack and stroke risk, supporting the consideration of 10-year risk estimates as early as age 30.

“The PREVENT score gives us a good educated guess, but keep in mind these numbers are pretty low when we talk about intermediate risk being a 5% to 10% 10-year risk,” Blumenthal told STAT News. “Some patients have already said, ‘Well, Dr. Blumenthal, that’s a 1 in 20 chance that I’ll get a cardiovascular event.’ That’s very true. But I tell them that if you have other factors that support earlier treatment, that may sway us to being more aggressive in your management.”

Beyond LDL and Statins: Other Influencing Factors

Beyond family history, several factors can elevate cardiovascular risk, including being overweight or obese, diabetes, and chronic kidney disease. Chronic inflammatory conditions like lupus or rheumatoid arthritis as well contribute. Individuals of South Asian or Filipino ancestry have a higher risk of developing atherosclerosis.

For women, the timing of atherosclerotic disease development typically lags about 10 years behind men. However, this delay can be erased by experiences like early premature menopause, preeclampsia, gestational diabetes, or hypertension during pregnancy. “If they have one of these reproductive risk markers of increased cardiovascular risk, then that, I consider, will lead to more clinicians and patients thinking about being much more aggressive in their lifestyle habits and, if necessary, using a medicine to lower their cholesterol,” Blumenthal said.

Recent attention has also focused on blood markers beyond traditional cholesterol levels. Lipoprotein(a), apolipoprotein B (ApoB), and high-sensitivity C-reactive protein are increasingly considered important indicators of risk. Lp(a), influenced by genetics and present in about 1 in 5 Americans, should be measured once in a lifetime, with levels of 50 mg/dL or higher associated with a roughly 40% increased long-term risk of heart attack or stroke. Lifestyle changes don’t affect Lp(a) levels, but high Lp(a) combined with high LDL may prompt a conversation about lowering LDL. ApoB may be a more accurate risk marker than LDL cholesterol in individuals with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides, or known cardiovascular disease who have reached their cholesterol goals.

The Role of Statins and Emerging Therapies

While the new guidelines encompass a broader approach, statins remain a cornerstone of cardiovascular disease prevention. Introduced in the 1980s, these medications have significantly reduced the incidence of heart attacks, strokes, and peripheral artery disease, and are available at a relatively low cost – around $40 per year. However, adherence to statin prescriptions remains a challenge.

Potential side effects, such as muscle pain and a slight increase in the risk of developing type 2 diabetes (estimated between 0.1% and 0.5% absolute risk increase), contribute to patient concerns. Blumenthal noted that 95% or more patients experience no difficulties with the medication. A recent study, highlighted by STAT News, found that many commonly reported side effects associated with statins may not be directly caused by the drugs themselves.

Beyond statins, other medications are available for cholesterol control, including PCSK9 inhibitors, which can further lower LDL cholesterol levels. Research presented at the American Heart Association’s scientific session in November 2025, and detailed in an editorial published in JACC and Circulation, suggests that PCSK9 inhibitors may be beneficial even before a first heart attack. However, their higher cost – potentially $5,000 per year – limits their widespread use compared to generic statins.

Coronary artery calcium (CAC) scans can also aid in risk assessment, particularly when uncertainty remains. These scans reveal calcium and plaque buildup in artery walls and are now recommended for men age 40 and up and women age 45 and up with borderline or intermediate 10-year risk.

Looking Ahead: A Focus on Patient Engagement

The most significant challenge, according to Blumenthal, lies in motivating individuals to adopt and maintain healthy lifestyle habits. He emphasized the importance of long-term exposure to healthy behaviors and the benefits of early intervention.

Jeremy Sussman, a primary care physician at the VA Ann Arbor Healthcare System, expressed concern that some patients might perceive statin therapy as overly aggressive. He also noted the lack of primary care physician representation in the guideline writing process and the need for a more patient-centered approach, given that many individuals discontinue cholesterol-lowering medications within two years of starting them. “The most difficult questions in dyslipidemia treatment are rarely if or when a patient has high enough risk or cholesterol level. It’s trying to understand the patient’s values and how doctors and patients together can decide if a patient should overcome their dislike of medicines to start a pill today for a goal of preventing a heart attack in 20 years,” he said.

The guidelines will be updated annually to incorporate new research and provide ongoing resources for physicians. The emphasis remains on a holistic approach to cardiovascular health, recognizing that early identification, lifestyle modifications, and appropriate medication use are all crucial components of prevention.